KZIAKAZIA THERAPEUTICS LTD

Nasdaq kaziatherapeutics.com


$ 0.38 $ 0.01 (1.78 %)    

Monday, 09-Sep-2024 13:32:51 EDT
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 0.378099
$ 0.38
$ 0.37 x 100
-- x --
$ 0.38 - $ 0.38
$ 0.19 - $ 1.58
121,600
na
8.62M
$ 0.99
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-07-2006 11-06-2006 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-kazia-therapeutics-maintains-2-price-target

HC Wainwright & Co. analyst Sean Lee reiterates Kazia Therapeutics (NASDAQ:KZIA) with a Buy and maintains $2 price target.

 whats-going-on-with-kazia-therapeutics-shares-thursday

Kazia Therapeutics announced results from its Phase II/III trial in regards to the treatment of glioblastoma, a type of brain c...

 kazia-therapeutics-shares-are-jumping-today-successful-study-for-brain-cancer-treatment

Kazia Therapeutics reports a 33% improvement in overall survival for newly diagnosed glioblastoma patients using paxalisib in a...

 kazia-to-present-dipg-data-at-ispno-june-29---july-2

Kazia Therapeutics Limited (NASDAQ:KZIA), a biotechnology company specialising in oncology, is pleased to announce the presenta...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION